A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT ID: NCT06335303

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

322 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-05

Study Completion Date

2026-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.

Participants are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1819479. Participants in 1 group get placebo. Placebo tablets look like BI 1819479 tablets, but do not contain any medicine. Participants take the treatment for 6 months to 1 year. Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site between 10 and 12 times and get up to 11 phone calls from the site staff.

At site visits doctors regularly perform breathing tests that measure how well the lungs are working. Researchers compare the results between participants who take BI 1819479 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 1819479 low dose treatment group

Group Type EXPERIMENTAL

BI 1819479

Intervention Type DRUG

BI 1819479

BI 1819479 medium dose treatment group

Group Type EXPERIMENTAL

BI 1819479

Intervention Type DRUG

BI 1819479

BI 1819479 high dose treatment group

Group Type EXPERIMENTAL

BI 1819479

Intervention Type DRUG

BI 1819479

Placebo group

Group Type PLACEBO_COMPARATOR

Placebo matching BI 1819479

Intervention Type DRUG

Placebo matching BI 1819479

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 1819479

BI 1819479

Intervention Type DRUG

Placebo matching BI 1819479

Placebo matching BI 1819479

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients ≥40 years old at the time of signed informed consent.
2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
3. Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
4. On stable treatment with nintedanib or pirfenidone for at least 12 weeks or not on treatment with either nintedanib or pirfenidone for at least 12 weeks
5. Forced Vital Capacity (FVC) ≥45% of predicted normal.
6. Diffusion capacity of the lung for carbon monoxide (DLCO) ≥25% of predicted normal corrected for hemoglobin (Hb).
7. Women of childbearing potential (WOCBP) must use highly effective methods of birth control with low user dependency and additional barrier contraception for male partners (use of condom) until end of follow-up period.
8. Male trial participants with WOCBP partners must use contraception (condom) to avoid exposure via seminal fluid. Female partners of male trial participants must use highly effective methods of contraception during treatment until end of follow-up period.

Exclusion Criteria

1. Acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) within at least 12 weeks prior to screening and/or during the screening period (investigator-determined).
2. Treated with immunosuppressive medications (other than oral corticosteroids) or prednisone \>15 mg/day or equivalent for respiratory or pulmonary reasons.
3. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
4. The patient is currently enrolled in another investigational device or drug trial, or their Visit 1 occurs less than 30 days or 5 half-lives (whichever is longer) after completing a previous investigational device or drug trial or receiving other investigational treatments.
5. Patients with a significant disease or condition other than the IPF under study, which in the opinion of the investigator, may put the patient at risk because of participation, interfere with trial procedures, or cause concern regarding the patient's ability to participate in the trial or any medical condition which could lead to a life expectancy \<12 months.
6. Relevant airways obstruction (pre-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) \<0.7).
7. In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
8. Lower respiratory tract infection requiring treatment within 4 weeks prior to Visit 1 and/or during the screening period.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Critical Care, Pulmonary and Sleep Associates

Lakewood, Colorado, United States

Site Status

Clinical Research Specialists LLC

Kissimmee, Florida, United States

Site Status

SEC Clinical Research

Pensacola, Florida, United States

Site Status

The Iowa Clinic, PC

West Des Moines, Iowa, United States

Site Status

Advanced Pulmonary Research

Warren, Michigan, United States

Site Status

Memorial Hospital Gulfport

Gulfport, Mississippi, United States

Site Status

Coastal Carolina Health Care, P.A. Pulmonary and Sleep Medicine

New Bern, North Carolina, United States

Site Status

Southeastern Research Center-Winston Salem-69289

Winston-Salem, North Carolina, United States

Site Status

Clinical Research Associates of Central PA

DuBois, Pennsylvania, United States

Site Status

Temple University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Lowcountry Lung and Critical Care

Charleston, South Carolina, United States

Site Status

Spartanburg Medical Research

Spartanburg, South Carolina, United States

Site Status

Clinical Trials Center of Middle Tennessee, LLC

Franklin, Tennessee, United States

Site Status

Pulmonary Associates of Richmond, Inc.

Richmond, Virginia, United States

Site Status

Centro de Investigaciones Metabolicas (CINME)-C.A.B.A-61553

C.a.b.a, , Argentina

Site Status

Hospital Britanico de Buenos Aires

CABA, , Argentina

Site Status

Centro de Investigación Clinica Belgrano

CABA, , Argentina

Site Status

CEDIC - Centro de Investigacion Clinica

CABA, , Argentina

Site Status

Consultorios Médicos del Buen Ayre

Capital Federal, , Argentina

Site Status

Canberra Hospital

Garran, Australian Capital Territory, Australia

Site Status

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Site Status

Launceston Respiratory & Sleep Centre

Launceston, Tasmania, Australia

Site Status

Lung Research Victoria

Footscray, Victoria, Australia

Site Status

Austin Hospital

Heidelberg, Victoria, Australia

Site Status

The Alfred Hospital

Melbourne, Victoria, Australia

Site Status

Institute for Respiratory Health

Nedlands, Western Australia, Australia

Site Status

Macquarie University

Macquarie Park, , Australia

Site Status

Medical University of Graz State Hospital - University Hospital Graz

Graz, , Austria

Site Status

Krems University Hospital

Krems, , Austria

Site Status

Kepler Univ. Klinikum Linz

Linz, , Austria

Site Status

Hospital Elisabethinen Linz

Linz, , Austria

Site Status

Standort Penzing der Klinik Ottakring

Vienna, , Austria

Site Status

Clinic Floridsdorf

Vienna, , Austria

Site Status

Klinikum Wels - Grieskirchen GmbH

Wels, , Austria

Site Status

Cliniques Universitaires Saint-Luc

Brussels, , Belgium

Site Status

CHR de la Citadelle

Liège, , Belgium

Site Status

Serviços Medicos Respirar Sul Fluminense

Barra Mansa, , Brazil

Site Status

Faculdade de Medicina de Botucatu - UNESP

Botucatu, , Brazil

Site Status

Hospital das Clínicas da UFG - EBSERH

Goiânia, , Brazil

Site Status

Irmandade da Santa Casa de Misericórdia de Porto Alegre

Porto Alegre, , Brazil

Site Status

Pesquisare

Santo André, , Brazil

Site Status

COE Sao Jose dos Campos

São José dos Campos, , Brazil

Site Status

Hospital Alemao Oswaldo Cruz

São Paulo, , Brazil

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

QEII Health Sciences Centre

Halifax, Nova Scotia, Canada

Site Status

Toronto General Hospital

Toronto, Ontario, Canada

Site Status

McGill University Health Centre (MUHC)

Montreal, Quebec, Canada

Site Status

Beijing Chao-Yang Hospital

Beijing, , China

Site Status

The Second Xiangya Hospital Of Central South University

Changsha, , China

Site Status

West China Hospital of Sichuan University

Chengdu, , China

Site Status

People's Hospital of Sichuan Province

Chengdu, , China

Site Status

First Affiliated Hospital of Guangzhou Medical University

Guangzhou, , China

Site Status

Hangzhou First People's Hospital

Hangzhou, , China

Site Status

Zhejiang Hospital

Hangzhou, , China

Site Status

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

Hangzhou, , China

Site Status

Anhui Provincial Hospital

Hefei, , China

Site Status

Nanjing Drum Tower Hospital

Nanjing, , China

Site Status

China Shenyang Chest Hospital

Shenyang, , China

Site Status

Tianjin Medical University General Hospital

Tianjin, , China

Site Status

Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T

Wuhan, , China

Site Status

Affiliated Hospital, Xuzhou Medical college

Xuzhou, , China

Site Status

Thomayer University Hospital

Prague, , Czechia

Site Status

University Hospital Bulovka

Prague, , Czechia

Site Status

Rigshospitalet-København Ø-69883

København Ø, , Denmark

Site Status

Odense University Hospital

Odense, , Denmark

Site Status

HYKS Keuhkosairauksien tutkimusyksikkö

Helsinki, , Finland

Site Status

Oulun yliopistollinen keskussairaala

Oulu, , Finland

Site Status

Tampereen yliopistollinen sairaala

Tampere, , Finland

Site Status

TYKS

Turku, , Finland

Site Status

HOP d'Angers

Angers, , France

Site Status

HOP Avicenne

Bobigny, , France

Site Status

HOP Louis Pradel

Bron, , France

Site Status

HOP CHU Caen

Caen, , France

Site Status

INS Coeur Poumon

Lille, , France

Site Status

HOP Nord

Marseille, , France

Site Status

HOP Pasteur

Nice, , France

Site Status

HOP Pontchaillou

Rennes, , France

Site Status

Pneumologische Praxis Dr. Löh

Bad Homburg, , Germany

Site Status

Charite Universitätsmedizin Berlin KöR

Berlin, , Germany

Site Status

Universitätsklinikum Bonn AöR

Bonn, , Germany

Site Status

Caritas-Krankenhaus St. Maria gGmbH

Donaustauf, , Germany

Site Status

Klinikum Fulda gAG

Fulda, , Germany

Site Status

Universitätsmedizin Greifswald

Greifswald, , Germany

Site Status

Klinikum Region Hannover GmbH

Hanover, , Germany

Site Status

Lungenklinik Hemer

Hemer, , Germany

Site Status

Lungenfachklinik Immenhausen

Immenhausen, , Germany

Site Status

Klinikum Konstanz

Konstanz, , Germany

Site Status

Universität Leipzig

Leipzig, , Germany

Site Status

Klinikum der Universität München AÖR

München, , Germany

Site Status

Hospital of Heraklion (PAGNI)

Crete, , Greece

Site Status

Univ. Gen. Hosp. of Ioannina

Ioannina, , Greece

Site Status

University of Debrecen Clinical Centre

Debrecen, , Hungary

Site Status

A. O. Universitaria Careggi

Florence, , Italy

Site Status

Ospedale Colonnello D Avanzo

Foggia, , Italy

Site Status

Ospedale G.B. Morgagni

Forlì, , Italy

Site Status

Azienda Ospedaliera San Martino

Genova, , Italy

Site Status

Ospedale Classificato San Giuseppe

Milan, , Italy

Site Status

Azienda Ospedaliera Universitaria di Padova

Padua, , Italy

Site Status

Pol. Universitario Tor Vergata

Roma, , Italy

Site Status

Fondazione Policlinico Universitario A. Gemelli IRCCS

Roma, , Italy

Site Status

Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza

Roma, , Italy

Site Status

Tosei General Hospital

Aichi, Seto, , Japan

Site Status

University of Fukui Hospital

Fukui, Yoshida-gun, , Japan

Site Status

National Hospital Organization Kyushu Medical Center

Fukuoka, Fukuoka, , Japan

Site Status

Kyushu University Hospital

Fukuoka, Fukuoka, , Japan

Site Status

Kanagawa Cardiovascular and Respiratory Center

Kanagawa, Yokohama, , Japan

Site Status

National Hospital Organization Kinki-Chuo Chest Medical Center

Osaka, Sakai, , Japan

Site Status

Hamamatsu University Hospital

Shizuoka, Hamamatsu, , Japan

Site Status

Tokushima University Hospital

Tokushima, Tokushima, , Japan

Site Status

Kyorin University Hospital

Tokyo, Mitaka, , Japan

Site Status

Toho University Omori Medical Center

Tokyo, Ota-ku, , Japan

Site Status

National Center for Global Health and Medicine

Tokyo, Shinjuku-ku, , Japan

Site Status

Hospital Sultan Idris Shah Serdang

Kajang, , Malaysia

Site Status

Institut Perubatan Respiratori

Kuala Lumpur, , Malaysia

Site Status

Sarawak General Hospital

Kuching, Sarawak, , Malaysia

Site Status

Waikato Hospital

Hamilton, , New Zealand

Site Status

Greenlane Clinical Centre

One Tree Hill, Auckland, , New Zealand

Site Status

Haukeland Universitetssykehus

Bergen, , Norway

Site Status

Akershus Universitetssykehus HF

Lørenskog, , Norway

Site Status

Clin.Hosp.Med.Univ.Marcinkowski in Poznan

Poznan, , Poland

Site Status

Alergopneuma Medical Center

Świdnik, , Poland

Site Status

Singapore General Hospital

Singapore, , Singapore

Site Status

Tan Tock Seng Hospital

Singapore, , Singapore

Site Status

The Catholic University of Korea, Bucheon St.Mary's Hospital

Bucheon-si, , South Korea

Site Status

Inje University Haeundae Paik Hospital

Busan, , South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam, , South Korea

Site Status

Inje University Sanggye Paik Hospital

Seoul, , South Korea

Site Status

Kyung Hee University Hospital

Seoul, , South Korea

Site Status

Severance Hospital

Seoul, , South Korea

Site Status

Soonchunhyang University Hospital Seoul

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Hospital General Universitario de Alicante

Alicante, , Spain

Site Status

Hospital Universitari Vall D Hebron

Barcelona, , Spain

Site Status

Hospital de Galdakao

Galdakao, , Spain

Site Status

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, , Spain

Site Status

Hospital La Princesa

Madrid, , Spain

Site Status

Hospital Universitario Infanta Leonor

Madrid, , Spain

Site Status

Hospital Virgen de la Victoria

Málaga, , Spain

Site Status

Hospital Central de Asturias

Oviedo, , Spain

Site Status

Hospital Universitario Marqués de Valdecilla

Santander, , Spain

Site Status

Hospital Clínico de Santiago

Santiago de Compostela, , Spain

Site Status

Hospital Virgen del Rocío

Seville, , Spain

Site Status

Karolinska University Hospital

Stockholm, , Sweden

Site Status

CTC Clinical Trial Consultants AB

Uppsala, , Sweden

Site Status

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Chang Gung Memorial Hospital, Linkou

Taoyuan District, , Taiwan

Site Status

Chulalongkorn Hospital

Bangkok, , Thailand

Site Status

Srinagarind Hospital

Khon Kaen, , Thailand

Site Status

Ramathibodi Hospital

Ratchathewi, , Thailand

Site Status

Songklanagarind Hospital

Thailand, , Thailand

Site Status

Heartlands Hospital

Birmingham, , United Kingdom

Site Status

Castle Hill Hospital

Cottingham, Hull, , United Kingdom

Site Status

Royal Devon and Exeter Hospital, Wonford

Exeter, , United Kingdom

Site Status

Royal Lancaster Infirmary

Lancaster, , United Kingdom

Site Status

St James's University Hospital

Leeds, , United Kingdom

Site Status

Royal Brompton Hospital

London, , United Kingdom

Site Status

Wythenshawe Hospital

Manchester, , United Kingdom

Site Status

Churchill Hospital

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Canada China Czechia Denmark Finland France Germany Greece Hungary Italy Japan Malaysia New Zealand Norway Poland Singapore South Korea Spain Sweden Taiwan Thailand United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-508395-11-00

Identifier Type: OTHER

Identifier Source: secondary_id

U1111-1302-4283

Identifier Type: OTHER

Identifier Source: secondary_id

1462-0004

Identifier Type: -

Identifier Source: org_study_id